Schinkel AH: P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36: 179–194. 10.1016/S0169-409X(98)00085-4
Article
CAS
PubMed
Google Scholar
Demeule M, Labelle M, Regina A, Berthelet F, Beliveau R: Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms. Biochem Biophys Res Commun 2001, 281: 827–834. 10.1006/bbrc.2001.4312
Article
CAS
PubMed
Google Scholar
Fromm MF: Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004, 25: 423–429. 10.1016/j.tips.2004.06.002
Article
CAS
PubMed
Google Scholar
de Lange EC: Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004, 56: 1793–1809. 10.1016/j.addr.2004.07.009
Article
CAS
PubMed
Google Scholar
Loscher W, Potschka H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2: 86–98. 10.1602/neurorx.2.1.86
Article
PubMed Central
PubMed
Google Scholar
Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW: Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002, 12: 535–541. 10.1097/00008571-200210000-00005
Article
CAS
PubMed
Google Scholar
Vogelgesang S, Glatzel M, Walker LC, Kroemer HK, Aguzzi A, Warzok RW: Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol 2006, 111: 436–443. 10.1007/s00401-006-0042-3
Article
CAS
PubMed
Google Scholar
Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de VR, de KO, van Oostrom JC, Portman A, Leenders KL: Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 2008, 115: 1001–1009. 10.1007/s00702-008-0030-y
Article
CAS
PubMed Central
PubMed
Google Scholar
van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EF, Hoetjes NJ, Tolboom N, Langer O, Müller M, Scheltens P, Lammertsma AA, van Berckel BNM: Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2011. doi: 10.1093/brain/awr298
Google Scholar
Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Müller M, Baumgartner C: Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48: 1774–1784. 10.1111/j.1528-1167.2007.01116.x
Article
CAS
PubMed
Google Scholar
Bartels AL, van Berckel BN, Lubberink M, Luurtsema G, Lammertsma AA, Leenders KL: Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord 2008, 14: 505–508. 10.1016/j.parkreldis.2007.11.007
Article
CAS
PubMed
Google Scholar
Bauer M, Karch R, Neumann F, Abrahim A, Wagner CC, Kletter K, Muller M, Zeitlinger M, Langer O: Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol 2009, 65: 941–946. 10.1007/s00228-009-0709-5
Article
CAS
PubMed Central
PubMed
Google Scholar
Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB: P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med 2010, 51: 559–566. 10.2967/jnumed.109.070151
Article
CAS
PubMed Central
PubMed
Google Scholar
Seneca N, Zoghbi SS, Liow JS, Kreisl W, Herscovitch P, Jenko K, Gladding RL, Taku A, Pike VW, Innis RB: Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med 2009, 50: 807–813. 10.2967/jnumed.108.058453
Article
CAS
PubMed Central
PubMed
Google Scholar
Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD: Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009, 86: 368–377. 10.1038/clpt.2009.138
Article
CAS
PubMed Central
PubMed
Google Scholar
Syvanen S, Hammarlund-Udenaes M: Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr Top Med Chem 2010, 10: 1799–1809. 10.2174/156802610792927997
Article
PubMed
Google Scholar
Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M: Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of l- and d-verapamil examined with a stable isotope technique. 1984. Br J Clin Pharmacol 2004, 58: S796-S803. 10.1111/j.1365-2125.2004.02299.x
Article
CAS
PubMed Central
PubMed
Google Scholar
Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ: Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006, 79: 540–548. 10.1016/j.clpt.2006.02.004
Article
CAS
PubMed
Google Scholar
Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA: Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 2007, 27: 424–433. 10.1038/sj.jcbfm.9600349
Article
CAS
PubMed
Google Scholar
Bartels AL, Kortekaas R, Bart J, Willemsen AT, de Klerk OL, de Vries JJ, van Oostrom JC, Leenders KL: Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 2009, 30: 1818–1824. 10.1016/j.neurobiolaging.2008.02.002
Article
CAS
PubMed
Google Scholar
Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, Kletter K, Loscher W, Muller M, Zeitlinger M, Langer O: A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 2009, 50: 1954–1961. 10.2967/jnumed.109.063289
Article
PubMed Central
PubMed
Google Scholar
Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Muller M, Loscher W, Zeitlinger M, Langer O: Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 2010, 30: 510–515. 10.1038/jcbfm.2009.265
Article
CAS
PubMed Central
PubMed
Google Scholar
Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, Unadkat JD: Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009, 50: 1267–1275. 10.2967/jnumed.108.059162
Article
CAS
PubMed Central
PubMed
Google Scholar
Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG: The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000, 26: 449–462. 10.1053/ctrv.2000.0194
Article
CAS
PubMed
Google Scholar
Didziapetris R, Japertas P, Avdeef A, Petrauskas A: Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003, 11: 391–406. 10.1080/10611860310001648248
Article
CAS
PubMed
Google Scholar
Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ: Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997, 38: 1614–1623.
CAS
PubMed
Google Scholar
Luurtsema G, Windhorst AD, Mooijer MP, Herscheid JD, Lammertsma AA, Franssen EJ: Fully automated high yield synthesis of (R)- and (S)-[C-11]verapamil for measuring P-glycoprotein function with positron emission tomography. J Labelled Compds Radiopharm 2002, 45: 1199–1207. 10.1002/jlcr.632
Article
CAS
Google Scholar
Boellaard R, van LA, van Balen SC, Hoving BG, Lammertsma AA: Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001, 28: 81–89. 10.1007/s002590000405
Article
CAS
PubMed
Google Scholar
Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ: Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005, 32: 87–93. 10.1016/j.nucmedbio.2004.06.007
Article
CAS
PubMed
Google Scholar
Mourik JE, Lubberink M, Klumpers UM, Comans EF, Lammertsma AA, Boellaard R: Partial volume corrected image derived input functions for dynamic PET brain studies: methodology and validation for [11C]flumazenil. Neuroimage 2008, 39: 1041–1050. 10.1016/j.neuroimage.2007.10.022
Article
PubMed
Google Scholar
Brix G, Doll J, Bellemann ME, Trojan H, Haberkorn U, Schmidlin P, Ostertag H: Use of scanner characteristics in iterative image reconstruction for high-resolution positron emission tomography studies of small animals. Eur J Nucl Med 1997, 24: 779–786.
CAS
PubMed
Google Scholar
Mourik JE, Lubberink M, van Velden FH, Kloet RW, van Berckel BN, Lammertsma AA, Boellaard R: In vivo validation of reconstruction-based resolution recovery for human brain studies. J Cereb Blood Flow Metab 2010, 30: 381–389. 10.1038/jcbfm.2009.225
Article
PubMed Central
PubMed
Google Scholar
Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, Holm S, Paulson OB, Knudsen GM: MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005, 24: 969–979. 10.1016/j.neuroimage.2004.10.017
Article
PubMed
Google Scholar
Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW, Hume SP, Grasby PM, Lammertsma AA: Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 1998, 8: 426–440. 10.1006/nimg.1998.0379
Article
CAS
PubMed
Google Scholar
Akaike H: A new look at the statistical model indentification. IEEE Trans Autom Contr 1974, 19: 716–723. 10.1109/TAC.1974.1100705
Article
Google Scholar
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1: 307–310.
Article
CAS
PubMed
Google Scholar